Speaking on TBPN, Johnson called peptides a psychological phenomenon and said a regular bedtime does more for growth hormone than peptides.
Recap by typeshit. Post by @tbpn on X.
Kalkine Media ties the attention on Lilly to orforglipron's progress, arguing a pill could scale cheaper than injectables and ease supply limits.
Smaller portions could become more common on shelves, with inflation and GLP-1 appetite changes both pushing food makers toward personal packs.
Chokshi notes the sales were 0.4% of Lilly's $23 billion quarter, and that Divi's Labs hasn't announced any role in making the drug.
Oral Wegovy brought in about $850 million in H1 2026 and holds over 80% of new US oral scripts. Lilly says Foundayo volume doubled in a month.
Kaydo calls retatrutide the most exciting obesity drug in the pipeline and explains its triple action on GLP-1, GIP and glucagon receptors before adding caveats.
On Longevity.Technology's podcast, the two contrast well-studied GLP-1 drugs with thinly tested compounds and discuss gray-market risks and testing.
Loading…